Browsing Tag
Rein Therapeutics
2 posts
Rein’s $57.5m financing buys LTI-03 time, but Phase 2 IPF data now carry the valuation
LTI-03 wins FDA Fast Track status as Rein deploys its $43.6m cash position behind a closely watched Phase 2 IPF readout due in 2026.
FDA lifts hold on Rein Therapeutics’ LTI-03 trial, reviving hopes for idiopathic pulmonary fibrosis treatment
FDA clears Rein Therapeutics to restart its Phase 2 trial of LTI-03 for idiopathic pulmonary fibrosis, restoring investor confidence and trial momentum.